ACADIA Pharmaceuticals (ACAD)
(Delayed Data from NSDQ)
$16.53 USD
+0.11 (0.67%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $16.54 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth F Momentum A VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ACAD 16.53 +0.11(0.67%)
Will ACAD be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ACAD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACAD
Acadia (ACAD) Up 10% Since Last Earnings Report: Can It Continue?
Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options
ACAD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Soleno Stock Up as FDA Accepts PWS Drug NDA Under Priority Review
Axsome (AXSM) Banks on Auvelity & Sunosi to Fuel Growth
Acadia (ACAD) Q2 Earnings Beat, Product Sales Drive Revenues
Other News for ACAD
Tracking Baker Brothers Portfolio - Q2 2024 Update
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Jim Cramer Believes In Dell CEO, Doesn't Like B&G Foods
Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again
3 Biotech Names To Target Now